Amaç: Periferik kandaki serum albümin seviyesi ve lenfosit sayısı ile hesaplanan hastaların immün-beslenme durumu yansıtan prognostik nutrisyon indeks (PNI) Türkiye’deki SLE hastalarında hastalık aktivitesi (SLEDAI-2K) arasındaki ilişkiyi göstermeyi PNI’nın aktivitesinin bağımsız bir prediktörü olduğunu amaçladık.
 Yöntem: PNI, 156 hastasında aşağıdaki formüle göre hesaplandı: 10 x değeri ...

INTRODUCTION Systemic Lupus Erythematosus (SLE) is an inflammatory autoimmune disease where an interplay between acute phase proteins and cytokines are involved in disease activation. AIM AND OBJECTIVES This case control study was performed to investigate interrelationship between high sensitivity C-reactive proteins (hs-CRP), Interleukin-6 (IL-6) levels and disease activity among SLE patient...

The results of studies on the CD3(+)CD8(+)CD28(-) cells in SLE are inconsistent since several analyses describe CD3(+)CD8(+)CD28(-) as either immunosuppressive or cytotoxic. The aim of this study is to inquire whether the quantitative changes of CD3(+)CD8(+)CD28(-) T lymphocytes subpopulation are related to the clinical status of patients with lupus nephritis. Evaluation of Foxp3 expression on ...

Background Systemic lupus erythematosus (SLE) is a complex autoimmune disease with multiorgan involvement. High activity may drive the development of comorbidities and safety events in SLE. Objectives To assess prevalence history at time Lupus Erythematosus Disease Activity Index (SLEDAI) assessment incidence newly diagnosed post-SLEDAI among prevalent cohort adult SLE patients ≥18 years old. M...

Bu çalışmada, sistemik lupus eritematozus (SLE) hastalarında nötrofil/lenfosit (NLO), trombosit/lenfosit (PLO), monosit/lenfosit (MLO) oranı gibi hematolojik belirteçlere ek olarak inflamatuar indeks (Sİİ), inflamasyon yanıt indeksi (SİYİ) ve agregat (SİAİ) yeni belirteçlerin SLE’de belirteci öneminin belirlenmesi, bu paramatrelerin SLE hastalık aktivitesi ile ilişkisinin değerlendirilmesi çok ...

OBJECTIVE To assess the safety, tolerability, biologic activity, and efficacy of belimumab in combination with standard of care therapy (SOC) in patients with active systemic lupus erythematosus (SLE). METHODS Patients with a Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score >/=4 (n = 449)...

INTRODUCTION The aim of this study was to examine whether circulating levels of the proinflammatory glycoprotein tenascin-C (TNC) are useful as an activity-specific or predictive biomarker in systemic lupus erythematosus (SLE). METHODS Serum TNC levels were determined by enzyme-linked immunosorbent assay at inception visit in a prospective cohort of 59 SLE patients, and in 65 healthy controls...

BACKGROUND Intravenous cyclophosphamide (IVCY) pulse therapy has been used for lupus nephritis since the latter half of the 1980s; it has been shown to be effective for lupus nephritis and vasculitis and has become a standard therapy for the diffuse proliferative type of lupus nephritis in adults. IVCY therapy has also come to be used in children. This paper reports the long-term outcomes of IV...

Objective—To examine the relation between fatigue, disease activity, damage, and quality of life measures in patients with systemic lupus erythematosus (SLE). Methods—Consecutive patients attending the University of Toronto Lupus Clinic were studied. Disease activity was assessed using the SLEDAI and SLAM-R and damage using the SLICC/ACR Damage index. Fatigue was measured by the Fatigue Severit...